Spyre Therapeutics (SYRE) took a hit Wednesday after its experimental rheumatoid arthritis treatment failed to pass muster in midstage testing.
But **** ysts are far more interested in Spyre's inflammatory bowel disease drugs. These conditions include ulcerative colitis and Crohn's disease.
"Even excluding all non-UC (ulcerative colitis) indications, our PT (price target) would remain at ~$115, well above current trading levels," Wedbush **** yst David Nierengarten said in a client note. "While we view the RS (rheumatoid arthritis) results as disappointing, we see limited impact to our core IBD-driven (inflammatory bowel disease) thesis."
Still, Spyre stock fell 1.8%, closing at 93.61. Shares are highly rated with a strong IBD Digital Relative Strength Rating of 98, putting the stock's 12-month performance in the leading 2% of all stocks.
Spyre's drug, dubbed SPY072, actually showed some effectiveness in patients with rheumatoid arthritis. But the results didn't pass the company's internal bar for advancement. Spyre is still testing SPY072 in other rheumatology indications, including psoriatic arthritis and axial spondyloarthritis.

#arthritis #testing #bowel

Abbott Laboratories (NYSE:ABT) has agreed to pay $670 million to settle claims involving about 2,000 people who alleged that its specialized preterm infant formulas contributed to necrotizing enterocolitis (NEC), a serious and potentially fatal bowel disease affecting premature infants. The settlement also resolves Abbott's appeal of a $495 million verdict involving an Illinois mother, after that judgment was upheld by a Missouri appeals court. Abbott did not admit liability and continues to maintain that its products are safe.
The bigger issue for investors is that the settlement does not fully end the litigation. Abbott says claims from as many as 12,700 people remain, although that figure includes duplicate and unsupported claims as well as cases where it is unclear which manufacturer's formula was used. More than 825 federal cases are consolidated in Chicago, with additional cases pending in state courts.
That makes the settlement both a cost and a potential step toward reducing uncertainty around the litigation.
The strongest argument for Abbott Laboratories (NYSE:ABT) is that the $670 million settlement could put a meaningful portion of the legal risk behind the company. Rather than continuing to spend years fighting individual cases and risking additional large jury awards, Abbott has chosen to settle with a sizable group of plaintiffs. The company said the agreement is intended to substantially resolve the broader litigation.
There is also an important distinction between the products involved in the lawsuits and Abbott's broader nutrition business. The litigation concerns specialized formulas and products used for premature infants in hospitals, rather than the ordinary infant formulas sold through stores. That limits the direct exposure of Abbott's wider consumer nutrition portfolio.

#cases #formulas #laboratories

Healthcare investors looking for long-term growth don't always have to choose between fast-growing companies and defensive businesses. Sometimes the more interesting decision is between two high-quality companies that are growing for entirely different reasons. Johnson & Johnson (NYSE:JNJ) continues to benefit from the breadth of its pharmaceutical and medical technology businesses, while Thermo Fisher's (NYSE:TMO) outlook increasingly depends on a recovery in life sciences spending after several difficult years.
Both companies reported encouraging results, but does steady diversification or an improving industry cycle offer the stronger long-term opportunity for investors? Let's take a look.
Johnson & Johnson's (NYSE:JNJ) pharmaceutical business was arguably the biggest contributor to its strong quarter, as it helped increase total sales, generating $16.38 billion in quarterly sales and exceeding **** ysts' estimate of $16.1 billion. The healthcare giant now expects its annual sales to be around $101.1 billion at the midpoint, compared with $100.8 billion ⁠previously. In another optimistic feat, it raised its adjusted earnings per share forecast to $11.68 at the midpoint, from a previous $11.55 per share.
The most impressive aspect for Johnson & Johnson (NYSE:JNJ), however, wasn't simply pharmaceutical growth but rather the company's ability to offset one of the largest patent cliffs in its portfolio, as it absorbed a significant patent-related decline in Stelara sales while still raising its full-year outlook. Revenue from Johnson & Johnson's (NYSE:JNJ) Stelara, which treats psoriasis, Crohn's disease, and other autoimmune conditions, dropped over 55% in the quarter to $740 million due to patent loss.
However, the company's cancer and newer immunology drugs can be seen countering this loss, as sales of Tremfya, its psoriasis and inflammatory bowel disease drug, rose 72.5% to $2 billion, considerably exceeding the estimate of $1.74 billion. Strong performance from newer drugs such as Tremfya suggests the company's pipeline is successfully offsetting losses from older products.

#billion #tremfya

Miranda Kerr has addressed the backlash she faced over her disciplined diet and wellness routine. The supermodel took to Instagram on August 21 to open up about her daily lifestyle that had been labelled as "unhinged habits".
"Some of my 'unhinged' habits are actually just the routines that make me feel my best. For me, that looks like avoiding foods that cause inflammation in my body, prioritizing sleep, and being really intentional about the little choices I make every day. I start each morning with noni juice (even though I'll be the first to admit it doesn't taste very good), I cut out alcohol and I'm usually in bed before 9pm," she penned in the caption. "Wellness looks different for everyone, so be sure to listen to your body and stay consistent with what makes you feel good."
Miranda shared a post that broke down the non-negotiable wellness practices she follows to ensure she feels her best. "Eating a gluten-free, egg-free and dairy-free diet to reduce inflammation," read the first slide in the carousel. Other practices included being in bed by 9pm and up at 5am, starting everyday with a shot of noni juice, never falling asleep in makeup, eating dinner with her kids at 5pm, avoiding alcohol, and using certified organic skincare from her brand KORA Organics.
Miranda Kerr is a former Victoria's Secret model (@ WireImage)
The criticism came after Miranda appeared on Kristin Cavallari's Let's be Honest podcast, where she explained that she changed her diet when she was diagnosed with proctitis, a form of irritable bowel syndrome, during her pregnancy with her second son six years ago.

#miranda #free #kerr #eating

Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.

#year #short

Spyre Therapeutics (SYRE) has surged more than 565% over the past year, driven by strong technical momentum.
Shares are trading at a new 3-year high.
SYRE maintains a 100% "Buy" technical opinion from Barchart.
Short interest is elevated at 13.81% of float, highlighting volatility and the need for disciplined risk management.
Valued at $9.5 billion, Spyre Therapeutics (SYRE) is a biotechnology company which aims to create inflammatory bowel disease products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection.

#syre #technical #short #valued

The Houston Texans have plenty of food and drink options for the 70,000-plus fans that will be at each of their home games at Reliant Stadium, but very few will get to experience the luxury of the stadium's new exclusive area just steps away from the field.
Similar to what the Astros offer with the Diamond Club or the Rockets with their Lexus Lounge, the Texans are introducing the BMW Lone Star Ballroom and BMW M Club Blue.
The Texans took what was a storage area in the bowels of the stadium and turned it into a swanky lounge located at field level, below the stands, with a window looking out to the tunnel where the visiting team will run out onto the field before games.
That kind of access to the field and players is something that has been missing from the only building the Houston Texans have known since they began play in 2002.
"It's real important to us when we talk about delivering a world-class fan experience that we understand what other venues, other buildings are doing, not only in the state, not only in the country, but worldwide," Houston Texans team president Mike Tomon said. "I think we have seen a lot more segmentation to the different markets, meaning, do you have a unique experience for a certain type of fan? So, we see that as a trend and we see the want to get closer to the team and the game element as a trend as well."

#houston #club #games

Back in the day, fans threw snowballs at Santa Claus in Philadelphia during a halftime show of an Eagles game at old Franklin Field. Thirty years later, when games were held in the concrete fortress known as Veterans Stadium, a makeshift courtroom and jail were built in the bowels of the stadium because a quick justice system was needed to deal with rowdies.
It's well-documented that it can be a harsh crowd in the City of Brotherly Love.
But you know who Philadelphia loved on Saturday night? Islam Makhachev. Dagestan may be over 5,000 miles from Philly, but the city embraced the UFC's welterweight champion in his first ***** le defense against Ian Machado Garry, in large part because of Ian Machado Garry. The fans didn't like him. Not as a challenger. Not as a person. Not as a potential spoiler. At one point during UFC 330's main event, a chant broke out that couldn't help but tip their hand.
"F*** Ian Garry!" the chant went. Thousands joined in.
It wasn't what you might call the friendly confines for the Irishman, who showed up with the daunting task of trying to overthrow the UFC's best pound-for-pound fighter. Vegas oddsmakers installed Garry as a sizable underdog, which in other towns might've been enough to sway some sentiment.

#back

The merger will create a publicly traded company focused on advancing Caldera's lead inflammatory bowel disease therapy, with financing expected to fund operations into 2029.
Synlogic (USOTC:SYBX) agreed to merge with privately held Caldera Therapeutics in an all-stock transaction to create a new public company.
A concurrent upsized private placement is expected to raise approximately $278 million to support development of CLD-423 through Phase 2 clinical trials.
The combined company will operate as Caldera Therapeutics and intends to list on the Nasdaq Capital Market under the ticker symbol CALD.
CLD-423 is a potential first-in-class bispecific antibody targeting TL1A and IL-23p19 for ulcerative colitis, Crohn's disease, and other immune-mediated disorders.

#disease #sybx

WORCESTER — While Chad Tracy sat inside his office at Polar Park around 5 p.m. on April 25, the former WooSox manager made a rare call to his wife, Emily, during the middle of a Triple-A game.
Drenched in sweat and coated in mulch from her fingertips to toes, Emily, who was in the middle of landscaping the front yard of their home in Fairfield, Ohio, answered the phone.
"I said, 'Darn, what did you get kicked out of the game for?'" Emily recalled. "He said, 'Em, are you sitting down?' You start to go into panic mode that something bad happened. But he told me a plane was coming to pick him up that night to go manage (the Boston Red Sox) in Baltimore the next day.
"I was speechless."
Nearly four hours after telling his wife he'd been named interim manager of the Boston Red Sox, Tracy rolled a black suitcase through the lower bowel of Polar Park and left to board a plane headed for Baltimore.

#emily #park #wife #game

How long does it take for pre-season optimism to disappear? For Hibernian, one game.
As head coach David Gray and captain Martin Boyle tried to make sense of their shocking defeat by Kosovan side FC Malisheva in the bowels of the Stadium Fadil Vokrri, Hibs fans were gathered outside.
You could hear the shouts of anger and demands for an apology from the irate travelling supporters as the rest of the squad headed for the team bus.
"You know what we put in for this club," shouted one furious fan.
Gray was clear that such anger was justified and that there was "no excuse" for an abject showing.

#hibernian #boyle #kosovan #malisheva

(NEXSTAR) – The Centers for Disease Control and Prevention has confirmed more than 800 cases of cyclosporiasis, a gastrointestinal illness that causes extreme diarrhea, across more than half of U.S. states. The grand total appears set to continue climbing as the agency is investigating more than 1,500 likely new cases.
The illness is cause by the cyclospora parasite, which enters the body through contaminated produce. If you're unlucky enough to ingest it, you may get stuck with weeks of watery diarrhea as well as "frequent and sometimes explosive bowel movements," according to the CDC.
The exact source of this massive outbreak isn't yet known, but in the past cyclospora has largely been found on fresh fruits and vegetables that were contaminated by irrigation water tainted with feces.
Map: Cases of 'explosive' diarrhea illness continue to climb
Historically, the most commonly contaminated foods were raspberries, basil, cilantro, green onions, snow peas, lettuce, mesclun and salad mixes. A study reviewing outbreaks since the 1990s found cyclospora may also have contaminated blackberries, watercress, mango, and vegetable trays.

Once again, Joshua Kimmich found himself in the bowels of a World Cup stadium, expected to explain the inexplicable.
For the German captain, his third World Cup ended in another disaster when his side was dealt a last-32 defeat by Paraguay - and yet, Kimmich appeared more composed compared to four years ago in Qatar.
Back then, Germany failed to reach the knock-out stage for the second time in the row, leaving Kimmich to speculate that he might fall into a "mental hole" due to the "worst day" of his career.
This time around, Kimmich, who played most of the World Cup as right back despite being a midfield general for Bayern Munich, also did not shy away from an honest ***** sment - but delivered it with mature, steadfast composure.
"I'll always have the power to give it another go. The one thing I'll never do is give up!" Kimmich said.

ST. PAUL, Minn., Nov. 20 (UPI) -- Chinese researchers say a new kind of bacteria-packed pill can quickly detect gastrointestinal disease and has the potential to replace invasive colonoscopies in screening for ulcerative colitis and other gut maladies.
The results of a mouse study published this week in an American Chemical Society journal are raising hopes that timely and accurate diagnosis of inflammatory bowel diseases such as colitis and Crohn's disease could be performed non-invasively in the future.
Colonoscopies, in which a flexible tube fitted with a camera is inserted into the *****

She has short bowel syndrome, and only the U.S. offers the treatment that keeps her alive. But her family’s humanitarian parole was suddenly revoked.

Now, two months later, DHS has reversed course.

Deysi Vargas’s 4-year-old has short bowel syndrome — a condition in which the body cannot absorb enough nutrients from food.

But the 28-year-old mother, who hails from Oaxaca, Mexico, now fears access to treatment could end at any moment.